Features April 2012 Issue

Device Shows it can Help Mitral Valve Patients Labeled High Surgical Risks

The MitraClip, which helps bind the leaflets of the mitral valve, is already in use in Europe.

For many patients with serious mitral valve regurgitation, surgery to repair or replace the defective valve are two options that each have a proven history of positive outcomes. But what about patients who have severe mitral regurgitation, but are at a high risk for surgery? The technology to help these patients appears close at hand. Results of the EVEREST II trial were published in the Jan. 10 issue of the Journal of the American College of Cardiology, and the research shows that the percutaneous MitraClip (Abbott) device reduced mitral regurgitation and improved clinical symptoms in a group of high surgical-risk patients.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.